Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Drug Use Results Survey of Tiotropium Bromide

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02177318

Acronym

COPD

Enrollment

3588

Registered

2014-06-27

Start date

2005-04-30

Completion date

Unknown

Last updated

2014-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings

Interventions

DRUGSpiriva (tiotropium bromide) inhalation capsules

Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Patients with COPD

Exclusion criteria

-There is no exclusion criterion, because this post marketing study (PMS) is observational survey under condition of normal clinical practice

Design outcomes

Primary

Measure	Time frame
Number of patients with adverse events	Up to 4 weeks after start of treatment
Number of patients with adverse drug reactions	Up to 4 weeks after start of treatment
Number of patients with serious adverse events	Up to 4 weeks after start of treatment

Secondary

Measure	Time frame
Physician's overall judgement by medical interview into four grades: 1. Improved 2. No Change 3. Aggravated 4.Unassessable	Up to 4 weeks after start of treatment

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026